Intralesional adalimumab for the treatment of refractory balanitis xerotica obliterans

JAMA Dermatol. 2013 Jan;149(1):23-4. doi: 10.1001/2013.jamadermatol.39.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adalimumab
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / therapeutic use*
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Balanitis Xerotica Obliterans / drug therapy*
  • Balanitis Xerotica Obliterans / pathology
  • Humans
  • Injections, Intralesional
  • Male
  • Middle Aged
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal, Humanized
  • Adalimumab